Inclisiran + Background lipid lowering therapy
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol
Trial Timeline
Jul 7, 2021 → Jan 13, 2023
NCT ID
NCT04807400About Inclisiran + Background lipid lowering therapy
Inclisiran + Background lipid lowering therapy is a phase 3 stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04807400. Target conditions include Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04807400 | Phase 3 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease